Previous studies have demonstrated that MCC950 treatment could reduce IL-1β production and attenuate the severity of lung ischemia-reperfusion injury (23), ulcerative colitis (24), myocardial infarction (25), multiple sclerosis (22), and liver transplantation (26). This evidence concerns the gene IL1B and ulcerative colitis.